Drug intelligence / Profile preview

autologous oral mucosal epithelial cell sheet

Development stage: Unknown
Lead developer: He Eye Hospital
Modality: Stem Cell Therapies → Cell Therapies
Administration: Ophthalmic

Overview

This autologous cell therapy consists of a sheet of epithelial cells cultured from a patient's own oral mucosal tissue. Developed by He Eye Hospital, it is designed to treat limbal stem cell deficiency (LSCD), a condition where the loss of stem cells at the edge of the cornea leads to corneal opacity and vision loss. By transplanting these oral mucosal epithelial stem cells onto the ocular surface, the therapy aims to reconstruct the corneal epithelium and restore visual function. This approach is particularly useful for patients with bilateral LSCD where healthy limbal tissue is unavailable for autografting.

Other names: cultured autologous oral mucosal epithelial cell sheetCOMICS

Beyond the preview

Go deeper on autologous oral mucosal epithelial cell sheet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on autologous oral mucosal epithelial cell sheet.

Explore the full profile